December 8, 2016
La Jolla, CA
Patent practice in the life sciences continues to evolve and change. In particular, the FDA has recently issued new rules that will significantly affect Hatch-Waxman litigation. We will discuss these new rules and suggest ways to best position companies in light of the changed rules. Similarly, we will discuss a recently concluded Hatch-Waxman case in the district of Delaware concerning Savella® milnacipran for the treatment of fibromyalgia, emphasizing ways to avoid the various issues that came up during litigation.
Finally, the differing views concerning obviousness came to a head in the Federal Circuit’s en banc decision in Apple v. Samsung. While not a life science case, this decision showcases the various views on obviousness held by different judges on the Federal Circuit and demonstrates the continued uncertainty in this critically important area of the law. Please join us as we address these issues and provide insight to help guide your practice.
Speakers:
M. Paul Barker
Howard W. Levine
Jeffrey D. Smyth
Cora R. Holt
Thursday, December 8, 2016
La Jolla, CA
9:15 – 9:45 a.m.
Registration
9:45 a.m. – 3:00 p.m.
Workshop and Lunch
Finnegan confirms that this activity has been certified for 4.5 hours of California MCLE.
There is no charge to attend. For more information, please contact Finnegan IP Programs.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.